Ignite Creation Date:
2025-12-25 @ 12:36 AM
Ignite Modification Date:
2026-01-25 @ 10:40 PM
Study NCT ID:
NCT03132467
Status:
COMPLETED
Last Update Posted:
2024-06-05
First Post:
2017-04-25
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer
Sponsor:
M.D. Anderson Cancer Center
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Anatomic Stage II Breast Cancer AJCC v8 | View |
| None | Anatomic Stage IIA Breast Cancer AJCC v8 | View |
| None | Anatomic Stage IIB Breast Cancer AJCC v8 | View |
| None | Anatomic Stage III Breast Cancer AJCC v8 | View |
| None | Anatomic Stage IIIA Breast Cancer AJCC v8 | View |
| None | Anatomic Stage IIIB Breast Cancer AJCC v8 | View |
| None | Anatomic Stage IIIC Breast Cancer AJCC v8 | View |
| None | Estrogen Receptor Positive | View |
| None | HER2/Neu Negative | View |
| None | Progesterone Receptor Positive | View |
| None | Prognostic Stage II Breast Cancer AJCC v8 | View |
| None | Prognostic Stage IIA Breast Cancer AJCC v8 | View |
| None | Prognostic Stage IIB Breast Cancer AJCC v8 | View |
| None | Prognostic Stage III Breast Cancer AJCC v8 | View |
| None | Prognostic Stage IIIA Breast Cancer AJCC v8 | View |
| None | Prognostic Stage IIIB Breast Cancer AJCC v8 | View |
| None | Prognostic Stage IIIC Breast Cancer AJCC v8 | View |
Keywords: